Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
NCT02020109 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2018-04-05
Summary
Retrospective evaluation on the effect of splenic irradiation on clinical and hematological response and toxicity in patients with chronic lymphatic leukaemia (CLL).
Conditions
- Leukemia, Chronic Lymphatic
Interventions
- RADIATION
-
splenic irradiation
Sponsors & Collaborators
-
Maastricht Radiation Oncology
lead OTHER
Principal Investigators
-
Jacques Borger, dr. · Maastro Clinic, The Netherlands
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2016-12-31
- Completion
- 2017-01-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
NCT00632359 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
NCT00759603 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
NCT00836043 ·Status: TERMINATED
-
CLL Therapy Approaches in Russia
NCT05140369 ·Status: ACTIVE_NOT_RECRUITING
-
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
NCT01358734 ·Status: COMPLETED ·Phase: PHASE2
-
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02437019 ·Status: APPROVED_FOR_MARKETING
-
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT05310591 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00439231 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01185886 ·Status: UNKNOWN
-
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)
NCT03421626 ·Status: COMPLETED
-
Observational Study in CLL Patients Receiving BR
NCT02381899 ·Status: COMPLETED
-
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
NCT01558167 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
NCT01010568 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00481091 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
NCT03280160 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02200848 ·Status: TERMINATED ·Phase: PHASE1
-
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
NCT01003769 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665 ·Status: COMPLETED ·Phase: PHASE2
-
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00469859 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
NCT02337829 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
NCT00774345 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT02538965 ·Status: COMPLETED ·Phase: PHASE2
-
Childhood Acute Lymphoblastic Leukaemia: Follow-Up
NCT03545659 ·Status: COMPLETED
-
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
NCT01732861 ·Status: COMPLETED ·Phase: PHASE1